Corporate Banner
Satellite Banner
qPCR
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Dimerix HIT Assay to Understand Receptor Interactions Applied to Kinase Targets

Published: Friday, May 31, 2013
Last Updated: Thursday, May 30, 2013
Bookmark and Share
Better understanding of receptor signalling, including effects arising from their functional interaction in heteromeric complexes, will progress drug development. Dimerix’s HIT assay is used to understand kinase heteromer signalling pathways.

Patents have now been granted for Dimerix’s Heteromer Investigation Technology (HIT) assay in the US, Europe, China and Australia, with applications pending in other jurisdictions.  Dimerix’s HIT assay enables a ligand responsive interrogation of a wide range of signalling pathways that can be triggered by a complex of at least two receptors (or proteins).  The assay can be utilised in high-throughput screening to obtain novel hits against the heteromer target and its components, or employed to better profile existing leads for signalling elicited through heteromer formation.  The broad application of Dimerix’s technology enables it to be licensed for a range of proximity-based reporter systems enabling optimal information and outcomes.

Most recently, an application of Dimerix’s assay to kinase heteromers has been reported.  A/Prof Kevin Pfleger, co-inventor of Dimerix’s assay technology, is senior author of a paper entitled ‘Profiling Epidermal Growth Factor Receptor and Heregulin Receptor Heteromerization Using Receptor Tyrosine Kinase Heteromer Investigation Technology’ published 20 May 2013 in PLOS ONE.

The study demonstrates the use of Dimerix’s HIT assay to investigate the heteromeric complexes formed by EGFR and HER3 receptors, and the effect on the Grb2 signalling pathway.  The data show that heteromerization of the receptors is required for HER3 to interact with Grb2, including evidence that this occurs via a transactivation mechanism.

Why is this important?  These kinase receptors are known to be involved in various human cancers.  Better understanding of receptor signalling, including effects arising from their functional interaction in heteromeric complexes, will progress drug development.  Indeed, the importance of EGFR-HER3 heteromerization has been demonstrated by other studies showing a beneficial effect of dual-action antibodies targeting both receptors. 

Dimerix’s assay not only provides a useful tool for interrogating heteromer signalling, but can also be used for high-throughput screening to identify hits against the heteromer as well as respective monomers.  In collaborative work with partners, Dimerix has enabled profiling and screening activities encompassing a range of proteins and signalling pathways.  Dimerix has strong expertise in the area of GPCRs and their various G-protein or beta-arrestin signalling pathways, including GPCR deorphanisation.

Dimerix’s internal research has used its assay in a core research program to develop an improved therapy for reduction of proteinuria in chronic kidney disease. Proteinuria is an indicator of ongoing kidney damage.

More information is available on Dimerix’s website: www.dimerix.com. To see a schematic of Dimerix’s assay for different reporter systems, please go to the Dimerix Platform section of our website.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Gene Analysis System Could Accelerate Pace of Research on the Space Station
The WetLab-2 system will enable spaceflight genomic studies involving a wide variety of biospecimen types in the unique microgravity environment of space.
Liquid Biopsy for NSCLC
'Liquid biopsy' blood test accurately detects key genetic mutations in most common form of lung cancer, study finds.
Rare DNA Will Have Nowhere To Hide
Two National Institutes of Health grants back Rice University effort to develop new diagnostics.
Seeing Cell to Cell Differences
Seeing differences between individual cells for first time explains symptoms of rare genetic disorders, finds penn study.
Circular RNAs Implicated in Cancer
Circular RNAs – like their protein counterparts – are also affected by genomic rearrangements in cancer, resulting in abnormal fusions.
Know Thy Helicobacter pylori
Non-invasive method for genotyping H.pylori developed.
Zika Test Authorized for Emergency Use
n response to a request from the CDC, the FDA has issued an Emergency Use Authorization (EUA) for a diagnostic tool for Zika virus that will be distributed to qualified laboratories.
Lighting Up Disease-Carrying Mosquitoes
Sandia’s QUASR enables speedy, accurate detection of West Nile and other viruses.
Ultra-Sensitive Test for Cancers, HIV
Test developed that is thousands of times more sensitive than current diagnostics.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!